Aptose Bioscienc SEC Filings

Aptose Biosciences Inc. disclosed in a Form 8-K that on August 13, 2025 it issued a press release reporting its results of operations and financial condition, which is furnished as Exhibit 99.1. The filing states the press release is furnished under General Instruction B.2 and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated. The Form 8-K also provides a cover page interactive XBRL file as Exhibit 104. The report is signed by William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

Aptose Biosciences reported a six-month net loss of $12.6 million and held $1.298 million of cash, cash equivalents and restricted cash as of June 30, 2025. Total liabilities were $19.962 million and the company reported negative shareholders' equity of $14.4 million and an accumulated deficit of $553.6 million, with current liabilities exceeding current assets by $5.7 million. Management explicitly states substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.

On the clinical front, the company is advancing tuspetinib in a Phase 1/2 TUSCANY trial. Ten newly diagnosed AML patients were dosed across 40 mg, 80 mg and 120 mg cohorts with complete remissions (CRs) and MRD-negativity reported at the 40 mg cohort and composite CRs reported at 80 mg and 120 mg; no dose-limiting toxicities were observed and escalation to 160 mg was announced. The company paused further development spending on luxeptinib to prioritize tuspetinib. Related-party financing with Hanmi includes a $10.0 million loan, a debt conversion of $1.538 million into 409,063 shares, and a facility up to $8.5 million with $5.6 million of advances disclosed as subsequent events.

Filing date: August 6, 2025. Aptose Biosciences, Inc. (APTO) filed a Form 8-K reporting a Regulation FD disclosure announcing a press release dated August 6, 2025, which is attached as Exhibit 99.1.

Regulatory note: The press release attached as Exhibit 99.1 is explicitly stated to not be deemed "filed" for purposes of Section 18 of the Exchange Act pursuant to General Instruction B.2. Item 9.01 lists Exhibit 99.1 (Press Release dated August 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Company details: Commission File No. 001-32001; EIN 98-1136802; principal executive office at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario M5K 1E6, Canada; phone (647) 479-9828. No securities are registered under Section 12(b). The form is signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer, dated August 6, 2025.

Nasdaq Stock Market LLC has submitted Form 25 to the SEC to remove Aptose Biosciences Inc. (APTO) common shares from listing and registration under Section 12(b) of the Exchange Act. The filing, dated 21 July 2025, states that both the exchange and the issuer have complied with the relevant provisions of 17 CFR 240.12d2-2 for striking or voluntarily withdrawing the securities. The notification is signed on Nasdaq’s behalf by Hearings Advisor Aravind Menon. No financial metrics, reasons for delisting, or additional corporate actions are disclosed in the document.

Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.

Key terms:

• Facility available in up to 5 advances (≤US$2.5 m each) through 31 Dec 2025; non-revolving.
• Interest: 6% fixed; balloon repayment of all principal and accrued interest on 31 Aug 2028.
• Secured by first-ranking liens on all present and after-acquired property of Aptose and guaranteed by subsidiaries.
• Purpose limited to continued clinical development and operating costs related to Tuspetinib, an AML therapy.
• Contains customary covenants and default provisions; any re-borrowings prohibited.

The filing also triggers Item 2.03 for creation of a direct financial obligation. The debt adds leverage but supplies non-dilutive capital for ongoing trials.

Aptose Biosciences Inc. (NASDAQ: APTO) filed a Form 8-K dated June 20, 2025 to disclose an Item 7.01 Regulation FD communication. The filing states that the company issued a press release on the same date, attached as Exhibit 99.1.

The 8-K expressly notes that, under General Instruction B.2, the press release is being “furnished” rather than “filed”, meaning it is not incorporated into Exchange Act reports unless specifically referenced. No financial results, strategic transactions, or operational updates are contained in the 8-K itself, and the exhibit text is not included in the filing excerpt provided.